Stockscreener 앱 받기
3.58
0.56%
0.02
전일 마감가:
$3.56
열려 있는:
$3.53
하루 거래량:
165.54K
Relative Volume:
0.57
시가총액:
$144.98M
수익:
-
순이익/손실:
$-58.75M
주가수익비율:
-0.8274
EPS:
-4.327
순현금흐름:
$-50.79M
1주 성능:
-5.54%
1개월 성능:
-12.68%
6개월 성능:
+12.93%
1년 성능:
+33.09%
1일 변동 폭
$3.5075
$3.62
1주일 범위
$3.41
$3.8999
52주 변동 폭
$2.23
$5.38
Onkure Therapeutics Inc Stock (OKUR) Company Profile
명칭
Onkure Therapeutics Inc
전화
(720) 307-2892
주소
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
3.58 | 159.15M | 0 | -58.75M | -50.79M | -4.327 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-30 | 개시 | Evercore ISI | Outperform |
| 2024-12-05 | 개시 | Leerink Partners | Outperform |
| 2024-10-10 | 개시 | Oppenheimer | Outperform |
| 2023-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-12-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | 개시 | William Blair | Outperform |
| 2023-08-28 | 개시 | H.C. Wainwright | Buy |
| 2023-07-03 | 개시 | BofA Securities | Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-01-27 | 개시 | Robert W. Baird | Outperform |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-22 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-04 | 개시 | Jefferies | Buy |
| 2021-05-04 | 개시 | Piper Sandler | Overweight |
| 2021-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Onkure Therapeutics Inc 주식(OKUR)의 최신 뉴스
Prosight Management, LP Reduces OnKure Therapeutics (OKUR) Stake in Second Quarter - GuruFocus
OnKure Therapeutics (OKUR): ADAR1 reports 5.5% stake as GP falls below 5% - Stock Titan
OnKure Therapeutics (OKUR) investor BVF discloses 8% stake plus 2.15M pre-funded warrants - Stock Titan
OnKure Therapeutics (OKUR) sees 3.6% passive stake reported by Trails Edge - Stock Titan
Oppenheimer Adjusts OnKure Therapeutics PT to $14 From $30, Maintains Outperform Rating - marketscreener.com
OKUR Q2 2026 Earnings: Narrower-Than-Expected Loss Points to Cost Discipline at Clinical-Stage BiotechEstimate Dispersion - vinanet.vn
OKUR Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 43.19%Revenue Recognition Risk - Vinanet
OnKure Reprices Underwater Stock Options to Boost Retention - TipRanks
Prosight entities report 2.4% OnKure Therapeutics (OKUR) stake in 13G/A - Stock Titan
OnKure Therapeutics (OKUR) Holds Steady at $4.14 as Biotech Consolidates Within Tight RangeEarnings Sentiment - dars.gov.et
Onkure Therapeutics Inc (OKUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LifeSci Capital Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
OnKure Therapeutics has cash runway into 2029 - BizWest
JonesTrading Maintains OnKure Therapeutics(OKUR.US) With Hold Rating - Moomoo
OnKure Therapeutics reports Q2 2026 net loss $15.3M; $176.4M cash runway into 2029 - TradingView
OKUR: IND-enabling PI3Ka programs advance toward 2027 filings, backed by $176M cash runway into 2029 - TradingView
OnKure Therapeutics, Inc. Q2 2026: Net loss $(30.5M) for 6M, EPS $(0.31) — 10-Q Summary - TradingView
OnKure Therapeutics (Nasdaq: OKUR) raises $150M to fund PI3Kα drugs - Stock Titan
OKUR: Q2 2026 net loss was $15.3M; cash reserves strengthened by $150M private placement - TradingView
OnKure Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Yahoo Finance
OnKure Therapeutics Rings the Closing Bell - Nasdaq
OnKure Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
OnKure Therapeutics, Inc. Revenue Breakdown – NASDAQ:OKUR - TradingView
OnKure Therapeutics Inc. (OKUR) Q1 2026 Earnings: Wider-than-Expected Net Loss Triggers 4.5% Stock DeclineAnalyst Drop Coverage - dars.gov.et
Vivo Capital LLC Invests $7.98 Million in OnKure Therapeutics, Inc. $OKUR - MarketBeat
Onkure Therapeutics Inc (OKUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Onkure Therapeutics Inc (OKUR) Balance Sheet - TradingKey
Onkure Therapeutics Inc (OKUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKUR|Onkure Therapeutics Inc|Price:4.050|Chg%:-0.070 - TradingKey
Onkure Therapeutics Inc (OKUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OnKure Therapeutics (OKUR) Slips 1.7% as Shares Test Key Support ZoneEMA Signal - vinanet.vn
Onkure Therapeutics Inc (OKUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Onkure Therapeutics Inc (OKUR) Institutional Confidence - TradingKey
Onkure Therapeutics Inc (OKUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Onkure Therapeutics Inc (OKUR) Cash Flow - TradingKey
Onkure Therapeutics Inc (OKUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKUR Q1 2026 Earnings: Wider-than-expected loss as clinical-stage biotech progresses pipelineBanking Earnings Report - vinanet.vn
Onkure Therapeutics Inc (OKUR) Income Statement - TradingKey
OKUR Options Volatility — NASDAQ:OKUR - TradingView
OKUR Options Chain — NASDAQ:OKUR - TradingView
Price to earnings forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
OnKure Therapeutics (OKUR) Rises 3.6% as Stock Approaches Key Resistance LevelATR Trailing Stop - dars.gov.et
Price to sales forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
H.C. Wainwright cuts OnKure stock price target to $21 on valuation changes - Investing.com
OKUR Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
OnKure Therapeutics Price Target Cut to $21.00/Share From $27.00 by HC Wainwright & Co. - Moomoo
H.C. Wainwright Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Cuts Target Price to $21 - Moomoo
OnKure Therapeutics Inc. (OKUR) Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Cycle Outlook - dars.gov.et
OnKure Therapeutics (OKUR) Declines 2.7% as Shares Test Key Support ZoneBuyback Factor - vinanet.vn
Enterprise value to revenue forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
Onkure Therapeutics Inc (OKUR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Onkure Therapeutics Inc 주식 (OKUR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Leverone Jason A. | Chief Financial Officer |
Jun 22 '26 |
Sale |
4.40 |
303 |
1,332 |
18,802 |
| Saccomano Nicholas A | President and CEO |
Mar 23 '26 |
Sale |
4.16 |
86 |
357 |
7,333 |
| Leverone Jason A. | Chief Financial Officer |
Mar 23 '26 |
Sale |
4.16 |
301 |
1,251 |
16,000 |
| Saccomano Nicholas A | President and CEO |
Dec 22 '25 |
Sale |
2.97 |
87 |
258 |
7,419 |
| Leverone Jason A. | Chief Financial Officer |
Dec 22 '25 |
Sale |
2.97 |
302 |
896 |
16,301 |
| Saccomano Nicholas A | President and CEO |
Sep 22 '25 |
Sale |
2.62 |
88 |
231 |
3,506 |
| Leverone Jason A. | Chief Financial Officer |
Sep 22 '25 |
Sale |
2.62 |
303 |
795 |
12,603 |
0.86%
0.31%
자본화:
|
볼륨(24시간):